Gene Therapy in CNS Disorder Market Poised for an Astonishing 29.3% CAGR Surge by 2031 | Growth Plus Reports

Newark, New Castle, USA, May 25, 2023 (GLOBE NEWSWIRE) — Growth Plus Reports studied and calculated the size of the global market for gene therapy in CNS disorders in 2022 and is expected to increase at a revenue CAGR of 29.3% during the forecast period 2023-2031.

Analysis of the global market for gene therapy in CNS disorders indicates the rise in revenue share is likely to increase significantly during the forecast period. A promising method for treating a variety of ailments is gene therapy. Gene therapy for CNS illnesses tries to send functioning genes to the brain or spinal cord to replace or repair damaged genes or to improve the expression of certain genes.

Key Takeaways: 

• The increasing number of patients with Alzheimer’s, and Parkinson’s, is driving the market revenue share.
• The government initiatives for effective treatment and prevention drive market demand.
• Recent advances in gene therapy for CNS illnesses include viral vectors, targeted gene editing, and non-viral delivery systems.

Request a Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/gene-therapy-in-cns-disorder-market/8886

                               Gene Therapy in CNS Disorder Market Scope

Recent Development in the Gene Therapy in CNS Disorder Market: 

• In November 2022, Leriglitazone, now being evaluated by the EMA for the orphan indication X-linked Adrenoleukodystrophy (X-ALD), is the subject of a licensing deal between Minoryx Therapeutics and the Neuraxpharm Group for the European market.

Competitive Landscape

A list of the prominent players operating in the gene therapy in CNS disorder market includes: 

• PTC Therapeutics, Inc.
• Voyager Therapeutics
• Spark Therapeutics
• Biogen
• Pfizer Inc.

Market Drivers and Restraints: 

The global gene therapy in CNS disorder market revenue is driven by the rising disease prevalence and awareness among the population for early detection and effective prevention and treatment measures for CNS disorders. 

However, gene therapy for CNS illnesses is currently being assessed for long-term safety, the gene therapy in CNS disorder market revenue growth is expected to be restrained. 

Market Segmentation: 

• Based on indication, the gene therapy in CNS disorder market is segmented into Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, motor neuron disease, Huntington’s disease, multiple sclerosis, adrenoleukodystrophy & metachromatic leukodystrophy, neuropathies, and batten disease.
• Based on type, gene therapy in the CNS disorder market is segmented into ex vivo and in vivo.
• Based on the end user, gene therapy in the CNS disorder market is segmented into hospitals, specialty clinics, and others.

Request for Customization – https://www.growthplusreports.com/inquiry/request-sample/gene-therapy-in-cns-disorder-market/8886

Segmentation By Indication

Based on the indication, the Alzheimer’s disease segment dominates the global gene therapy in the CNS disorder market with the largest revenue share. Alzheimer’s disease affects brain function gradually and irreversibly, leading to memory loss, cognitive decline, and behavioral abnormalities. Preclinical research on gene therapy for Alzheimer’s disease has shown encouraging results, and various clinical trials are currently being conducted. Gene therapy is still in its early phases. As a result, this sector’s overall revenue is growing.

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global gene therapy in the CNS disorder market. This large revenue share is attributed to the prevalence of disease with a piece of proper knowledge and awareness in North America, favorable reimbursement policies, a well-established healthcare system, and sufficient funds for R&D. 

Report Coverage 

Growth Plus Reports conducted extensive research on the world market for gene therapy in CNS disorders. We looked at the basic market traits, important investment spheres, regional growth analytics, ten years of revenue projections, rival market players, and mergers and acquisitions.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
   3. Regulatory Landscape
   4. Reimbursement Scenario 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL GENE THERAPY IN CNS DISORDER MARKET – ANALYSIS & FORECAST, BY INDICATION
   1. Alzheimer’s Disease
   2. Huntington’s Disease 
   3. Parkinson’s Disease
   4. Amyotrophic Lateral Sclerosis
   5. Motor Neuron Disease
   6. Multiple Sclerosis
   7. Adrenoleukodystrophy & Metachromatic Leukodystrophy
   8. Neuropathies
   9. Batten Disease
6. GLOBAL GENE THERAPY IN CNS DISORDER MARKET – ANALYSIS & FORECAST, BY TYPE
   1. Ex Vivo
   2. In Vivo
7. GLOBAL GENE THERAPY IN CNS DISORDER MARKET – ANALYSIS & FORECAST, BY END USER
   1. Hospitals 
   2. Speciality Clinics 
   3. Others

GENE THERAPY IN CNS DISORDER MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8886

 VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Knee Arthrodesis Implants Market by Product Type (Standard Implants, Customized Implants), Technique (Long Intramedullary Nail, Short Intramedullary Nail), Implantation Technique (Cemented Implantation), End User (Hospitals & Clinics, Emergency Service Centers) – Global Outlook & Forecast 2023-2031

Oncology Imaging Software Market by Indication (Breast Cancer, Lung Cancer), Imaging Technique (CT Scan, MRI), Mode of Delivery (On-cloud, On-premise) – Global Outlook & Forecast 2023-2031

Acute Kidney Injuries Market by Type of Injuries (Pre-renal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injuries, Post-renal Acute Kidney Injuries), Treatment (Drug Therapy, Dialysis) – Global Outlook and Forecast 2023-2031

Mirvetuximab Soravtansine Market by Indication (Ovarian Cancer, Fallopian Tube Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Calcium Homeostasis Drugs Market by Drug Class (Calcium Metabolism Modifiers, Parathyroid Hormone Analogs), Indication (Hypocalcemia, Hypercalcemia), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Unleashing the Power of Innovation in Med Tech https://growthplusmedtechroundup.com/

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.